Longevity of Genotype-Specific Immune Responses to Plasmodium falciparum Merozoite Surface Protein 1 in Kenyan Children from Regions of Different Malaria Transmission Intensity by Bowman, Natalie M. et al.
Am. J. Trop. Med. Hyg., 95(3), 2016, pp. 580–587
doi:10.4269/ajtmh.15-0710
Copyright © 2016 by The American Society of Tropical Medicine and Hygiene
Longevity of Genotype-Specific Immune Responses to Plasmodium falciparum Merozoite
Surface Protein 1 in Kenyan Children from Regions of Different Malaria Transmission Intensity
Natalie M. Bowman,1 Jonathan J. Juliano,1,2,3* Cynthia J. Snider,2 Oksana Kharabora,1 Steven R. Meshnick,2 John Vulule,4
Chandy C. John,5 and Ann M. Moormann6
1Division of Infectious Diseases, University of North Carolina, School of Medicine, Chapel Hill, North Carolina; 2Department of Epidemiology,
Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 3Curriculum in Genetics
and Molecular Biology, University of North Carolina, Chapel Hill, North Carolina; 4Center for Global Health Research, Kenya Medical Research
Institute, Kisumu, Kenya; 5Ryan White Center for Pediatric Infectious Disease and Global Health, Indiana University, Indianapolis, Indiana;
6Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts
Abstract. Naturally acquired immunity to Plasmodium falciparum presents a changing landscape as malaria control
programs and vaccine initiatives are implemented. Determining which immunologic indicators remain surrogates of
past infection, as opposed to mediators of protection, led us to compare stability of immune responses across regions
with divergent malaria transmission intensities. A repeat cross-sectional study of Kenyan children from a malaria-
holoendemic area and an epidemic-prone area was used to examine longitudinal antibody and interferon-gamma (IFN-γ)
responses to the 3D7 and FVO variants of merozoite surface protein 1 (MSP1). Antibodies to MSP1 were common in both
study populations and did not significantly wane over a 21-month time period. IFN-γ responses were less frequent and
rapidly disappeared in children after a prolonged period of no malaria transmission. Antibody and IFN-γ responses
rarely correlated with each other; however, MSP1-specific IFN-γ response correlated with lack of concurrent
P. falciparum parasitemia of the same genotype, though only statistically significantly in the malaria-holoendemic region
(odds ratio = 0.31, 95% confidence interval = 0.12–0.84). This study affirms that antimalarial antibodies are informative
for evaluation of history of malaria exposure within individuals, whereas cell-mediated immunity, though short lived
under natural exposure conditions, might provide an assessment of recent infection and protection from parasitemia.
INTRODUCTION
Plasmodium falciparum causes the most severe form of
malaria, resulting in nearly 200 million cases and over
500,000 deaths in 2013.1 Burden of disease falls most heavily
on children in sub-Saharan Africa, where the majority of
both infections and deaths occur. Vector control, bed nets,
and other interventions have decreased the incidence of
malaria in many endemic areas, but an effective vaccine
will be necessary to realize the goal of malaria elimination.2
Development of an effective vaccine has been hindered by
our limited understanding of how immunologic memory to
malaria is developed and sustained in humans and by diffi-
culty in selecting malaria antigens that confer protective
immunity as vaccine candidates.3
Immunity to clinical malaria develops gradually during
childhood in endemic areas, but immunity is not steriliz-
ing, as asymptomatic parasitemia is common in older chil-
dren and adults living in areas of high transmission. In the
absence of frequent exposure to P. falciparum, immunity to
clinical disease wanes rapidly.4,5 The importance of humoral
immunity was established in 1961, when infused gamma
globulin was shown to be an effective treatment of experi-
mental malaria infections.6 The critical role for antibodies
in establishing clinical immunity appears to be their ability
to reduce the density of blood-stage parasitemia, thereby
preventing severe manifestations of malaria infection.7,8 Anti-
bodies to most blood-stage vaccine candidate antigens pre-
vent merozoites from attaching to and invading red blood
cells, but which antibody or combination of antibodies confer
protection from clinical malaria is unknown.8,9 Deconvoluting
antimalarial immunity is further complicated by a vaccine
antigen’s ability to induce cross-reactive antibodies between
different antigenic variants with shared epitopes, as has
been seen for merozoite surface protein 1 (MSP1).10 The
role of cell-mediated immunity is not as well characterized.
Interferon-gamma (IFN-γ) responses appear to be protec-
tive against P. falciparum infection but are short lived or fall
below the level of detection11–15; however, T cells likely play
an important role in control of P. falciparum infections both
directly and indirectly via interactions with B cells.16
MSP1, the most abundant surface protein on P. falciparum
merozoites, is a malaria vaccine candidate. During schizog-
ony, MSP1 undergoes several cleavage reactions. The 42-kDa
region at the C-terminal (MSP142) is cleaved into 19- and
33-kDa fragments (MSP119 and MSP133, respectively) during
merozoite invasion.17,18 MSP119 contains conserved B-cell epi-
topes, whereas MSP133 contains T-cell epitopes.
19–21 Immune
responses to these antigens as measured by enzyme-linked
immunosorbent assay and enzyme-linked immunosorbent spot
assays (ELISPOT) assays may serve as useful correlates of
vaccine efficacy. A recent meta-analysis of population-based
cohort studies found that individuals with IgG responses to
the MPS119 antigen had lower risk of clinical malaria than
those without IgG responses.9 However, at least one study
has shown that as a vaccine candidate, MSP119 alone is not
protective unless the MSP133 fragment is included to pro-
voke cell-mediated responses.21 Thus, a better understanding
of the relative contributions of humoral and cellular immu-
nity to MSP1 are necessary for continued development and
evaluation of this vaccine candidate.
Studies of naturally acquired malaria infections and clini-
cal outcomes have been used to gain a fuller understand-
ing of the development and maintenance of immunity to
malaria. To recapitulate this goal, we analyzed responses to
B- and T-cell epitopes from two MSP1 genotypes (3D7 and
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FVO) at two time points in a cohort of Kenyan children
living in Kisumu, a region with holoendemic malaria, and
Nandi, a highland region with hypoendemic malaria. Impor-
tantly, Nandi experienced an epidemic shortly before the
first time point, exposing children with little prior exposure
to a significant malaria burden, followed by regression to
very low transmission intensity. This cohort allows us to com-
pare individual immune responses of children who experi-
enced persistent malaria exposure in Kisumu to those rarely
exposed in Nandi.
MATERIALS AND METHODS
Study sites and population. We performed a secondary
analysis of data collected for a study of the relationship
between malaria and Epstein–Barr virus22 (see Supplemental
Information). Clinical data and blood samples for microscopy,
immunological testing, and parasite genotyping were col-
lected from study participants approximately every 6 months.
Infection with P. falciparum was determined by microscopy
of thick and thin blood smears, and cases were defined as
those with detectable blood-stage P. falciparum parasite. For
this analysis, we focused on samples collected at two time
points: February 2003 and November 2004. Although malaria
is holoendemic in Kisumu, there are relative peaks in trans-
mission intensity after the long rains (March–May) and short
rains (October–December).23 Transmission intensity varied in
Nandi, where in February 2003, there was a peak in malaria
transmission, but between February 2003 and November
2004, there was little malaria reported.24,25
MSP1 antibody levels and IFN-γ ELISPOT. Recombinant
antigens for the 3D7 and FVO genotypes of the MSP142
antigen were expressed as described elsewhere.15,22 Testing
for MSP1 antibodies used the same approach as previously
described.26 IgG specific for the MSP142 3D7 and MSP142
FVO were detected using a bio-Plex (Hercules, CA) bead-
based assay. One thousand beads of each malaria antigen were
then placed in wells with plasma from participants and diluted
to 1:5,000. Included on each plate were negative controls
(U.S. residents with no history of malaria) and positive con-
trols (pooled samples from Kisumu residents). Although anti-
body results were calculated as mean fluorescence intensity
(MFI), slight plate-to-plate variation necessitated standardi-
zation of results by expressing them in arbitrary units (AU).
For each plate, the participant’s AU values were calculated
by dividing each participant’s MFI antibody response by
the negative controls’ mean MFI plus three standard devia-
tions. AU values greater than 1.0 indicated a positive IgG
response. Cellular responses were determined by ELISPOT
for IFN-γ as described previously.27,28 In brief, peripheral
blood mononuclear cells were incubated for 84 hours with
5 μL MSP142 3D7 or FVO antigen and the number of spot-
forming units in the well was counted. A positive ELISPOT
response was defined as a number of spot-forming units that
was significantly greater than the number in the negative
control well by Fisher’s exact test with P < 0.05 (additional
details are in the Supplemental Information).
MSP1 genotyping. The block 16 section of the MSP1 gene,
corresponding to T-cell epitopes in the MSP133 fragment,
was then analyzed as previously described using allele-
restricted polymerase chain reaction.29 Details are provided
in the Supplemental Information.
Statistical analyses. We analyzed cross-sectional data at
each time point stratified by site because prevalence of
parasitemia was very strongly correlated with residence in
Kisumu, and site was an effect measure modifier for many of
the analyses. Primary outcomes were presence and magni-
tude of antibody response, presence and magnitude of
genotype-specific ELISPOT test, and parasitemia with specific
genotypes, measured in February 2003 and November 2004.
Exposures included age, sex, markers of immune function,
and parasitemia. In bivariate analysis, dichotomous or poly-
omatous variables were compared using χ2 and Cochran–
Armitage trend tests; continuous and ordinal variables were
compared using Student’s t test or linear regression for data
that were normally distributed and Wilcoxon rank-sum or
signed rank tests for data that were not. Spearman’s rank
correlation coefficient was used to assess correlation among
the different P. falciparum antibodies measured as continu-
ous AU values and ELISPOT responses. Children who had
mixed infections with both 3D7 and FVO genotypes were
included in analyses for each genotype when correlations
between presence of antibody or IFN-γ response and a spe-
cific genotype were performed. Data analysis was performed
in Stata 12 (StataCorp, College Station, TX) and SAS 9.2
(SAS, Cary, NC).
Ethical considerations. Informed consent was obtained
from each child’s parent or guardian before study enroll-
ment. The original study was approved by the Institutional
Review Board at University Hospitals of Cleveland, Case
Western Reserve University (AM’s affiliation at the time)
and the Ethical Review Committee of the Kenya Medical
Research Institute. This analysis was exempted by the insti-
tutional review boards at the University of North Carolina
at Chapel Hill and the University of Massachusetts Medi-
cal School.
RESULTS
Study population characteristics. There were 210 children
sampled in February 2003 and 174 in November 2004. There
were no statistical differences between children sampled at
both time points and those who dropped out with respect to
sex, study site, or prevalence of parasitemia in February 2003.
Additional patient characteristics are described in Table 1
and the Supplemental Information.
Parasitemia rates and parasite genotyping. As expected,
P. falciparum parasitemia was much more common in chil-
dren residing in holoendemic Kisumu (Table 1). Prevalence
of parasitemia increased with time in Kisumu, whereas in
Nandi, it declined precipitously between February 2003 and
November 2004, when only one child (1%) in Nandi was
parasitemic. In Nandi, parasitemic children were 3.8 years
older than nonparasitemic children in February 2003
(P = 0.007). Age was not related to parasitemia in Kisumu.
Sex was not related to parasitemia in Kisumu, but females
had higher prevalence of parasitemia than males in Nandi
in 2003 (odds ratio [OR] = 15.67, 95% confidence interval
[CI] = 2.18, 681.37).
Genotyping was performed on samples from participants
that were parasitemic by microscopy. Of these, approximately
90% were successfully amplified. Parasites containing the
3D7 MSP1 genotype were much more common than the
FVO MSP1 genotype (Table 1).
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MSP142 humoral immune responses. The median magni-
tude of antibody response to both antigens were higher in
Kisumu than in Nandi except in 2003, when there was no dif-
ference for FVO (Figure 1A and B, Supplemental Table 1,
Supplemental Information). In Kisumu, the prevalence of
detectable IgG response increased between surveys for both
antigens (P ≤ 0.04); however, there was a nonsignificant
decrease in Nandi. The median antibody response signifi-
cantly increased in magnitude between surveys in Kisumu.
In Nandi, the opposite was seen, with decreasing magnitude
in response to both antigens between surveys.
Most children with a positive antibody response in Feb-
ruary 2003 retained it in November 2004. In Kisumu, 93%
of responders to MSP142-3D7 and 88% of responders to
MSP142-FVO remained seropositive to the same antigen; in
Nandi, 80% and 74% retained responses to MSP142-3D7 and
MSP142-FVO, respectively. Neither age nor sex were signifi-
cantly associated with odds of retention of antibody response
(Table 2).
Age and sex had little effect on immunity. Age was mod-
estly associated with antibody response only to FVO in 2004
in Kisumu (OR = 1.14, 95% CI = 1.01–1.28). Magnitude of
antibody response increased modestly but significantly with
age for both antigens at both time points in Nandi (OR =
1.11–1.21), but in Kisumu, this relationship was only statisti-
cally significant for MSP142-3D7 in 2004 (OR = 1.37, 95%
CI = 1.13–1.68). Female children were more likely to have
positive antibody responses in Nandi but less likely in Kisumu,
though this finding was only significant for MSP142-FVO in
2004 in Kisumu (OR = 0.20, 95% CI = 0.06–0.67).
FIGURE 1. Merozoite surface protein 142 humoral and cell-mediated immune responses. Panels (A) and (B) show humoral immune responses
to recombinant 3D7 and FVO antigen, respectively. Data is presented as arbitrary units as described in the Materials and Methods section.
The box represents the 25th to 75th percentile, with whiskers extending to the maximum and minimum values. Panels (C) and (D) show cell-
mediated immune response for 3D7 and FVO recombinant antigen, respectively, and is plotted in a similar manner.
TABLE 1
Parasitemia and genotype data in Kisumu and Nandi
Kisumu (lowland) Nandi (highland)
Demographic data
Mean age (SD) 7.62 (0.38) 7.91 (0.35)
Female sex 62 (50%) 53 (55%)
Plasmodium falciparum parasitemia
February 2003 73 (79%) 14 (12%)
November 2004 65 (88%) 1 (1%)
Genotype in February 2003*
3D7 57 (79%) 10 (71%)
FVO 1 (1%) 0
Mixed 9 (13%) 1 (7%)
No amplification 5 (7%) 3 (21%)
Not parasitemic 20 104
Genotype in November 2004*
3D7 29 (50%) 0
FVO 1 (2%) 0
Mixed 10 (17%) 0
No amplification 18 (31%) 1 (100%)
Not parasitemic 16 99
SD = standard deviation. In February 2003, there were 92 observations in Kisumu and 118
in Nandi, and in November 2004, there were 74 observations in Kisumu and 100 in Nandi.
*Percentages are of P. falciparum microscopy-positive samples.
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Presence of a positive MSP142 antibody response to a
given allele was not associated with current parasitemia with
the same genotype at either site in either year. Magnitude of
antibody response was only associated with parasitemia dur-
ing the malaria epidemic in 2003 in Nandi, where infection
with the 3D7 genotype of P. falciparum was associated with
greater magnitude of antibody response to both MSP142-3D7
(P < 0.005) and MSP142-FVO (P = 0.001).
MSP142 cellular immune responses. Patterns of IFN-γ
ELISPOT responses to 3D7 and FVO variants of MSP142
varied between sites with different levels of transmission as
shown in Figure 1C and D. Both prevalence and magnitude
of ELISPOT response to MSP142-3D7 increased slightly in
Kisumu from 2003 to 2004; in Nandi, prevalence and magni-
tude of ELISPOT response to MSP142-3D7 decreased signifi-
cantly (Supplemental Table 2, Supplemental Information).
The magnitude of 3D7 ELISPOT (among those with a posi-
tive test) was significantly higher in Nandi than in Kisumu in
February 2003 (P < 0.0005). In November 2004, however,
the magnitude of 3D7 ELISPOT response was slightly higher
in Kisumu, though this was not significant. In Kisumu,
the magnitude of 3D7 ELISPOT response increased slightly
(P < 0.0005) but decreased nonsignificantly in Nandi (P = 0.07).
Very few children at either site responded to MSP142-FVO
except in Nandi in February 2003, when 17% of the children
responded. The number of positive ELISPOT responses to
MSP142-FVO was too small to draw conclusions, but trends
were similar to those seen for 3D7 genotype.
ELISPOT responses were not sustained between time
points: of children with a positive MSP142-3D7 ELISPOT
in February 2003, only 21% in Nandi and 36% in Kisumu
retained a positive response, and no child with a positive
IFN-γ ELISPOT for FVO in 2003 retained it. As shown in
Table 2, children were more likely to retain responses to
MSP142-3D7 in Kisumu than in Nandi, though the associa-
tion did not reach statistical significance. Neither age nor sex
was associated with retention of ELISPOT response.
Magnitude of IFN-γ ELISPOT responses to both antigens
increased with age in Kisumu in 2004 (P = 0.003 for both
antigens), as did prevalence of positive response (P = 0.02
for 3D7; P = 0.008 for FVO); in Nandi, this relationship was
only significant for the prevalence of MSP142-3D7 ELISPOT
response in 2004 (P = 0.009). Neither prevalence nor magni-
tude of ELISPOT responses differed by sex.
Positive IFN-γ ELISPOT response correlated with absence
of infection with the same genotype at both sites in 2003,
though only statistically significantly in Kisumu (Table 3).
Because of scarcity of immune responses and parasitemia in
Nandi, we were unable to calculate statistics for other time
points and parasite-immune response combinations at that
site. Magnitude of ELISPOT response was not associated
with parasitemia except in Kisumu in 2003, when increased
response to MSP142-3D7 modestly reduced odds of para-
sitemia with 3D7 (OR = 0.94, 95% CI = 0.89–0.99).
Relationships between humoral and cellular immune
responses to MSP142. In February 2003, presence of positive
IFN-γ ELISPOT results for different MSP142 genotypes were
significantly associated in Nandi (OR = 31.64, 95% CI =
4.44–1,340) but not Kisumu (OR = 2.15, 95% CI = 0.15–
30.94). In November 2004, data were too sparse to calculate
OR, but when stratified by site, this relationship was again
only significant in Nandi (P = 0.002; P = 0.06 in Kisumu).
As shown in Table 4, magnitude of humoral responses to
3D7 and FVO MSP142 antigens were correlated, but magni-
tude of cellular responses were rarely correlated to each
other or to humoral responses. In Kisumu (Table 4), IFN-γ
ELISPOT response to MSP142-3D7 antigen was correlated
to the 3D7 antibody response in 2004 and to the FVO anti-
body response in 2003 but not 2004; and in 2004, humoral
and cellular responses to the MSP1-FVO antigen were corre-
lated. In Nandi (Table 5) in 2004, MSP142-FVO ELISPOT
response was correlated to antibody response to MSP142-
FVO and to ELISPOT response to MSP142-3D7. There
was no evidence of synergy between humoral and cellular
responses to protect against concurrent parasitemia with
either genotype at either time point or site.
DISCUSSION
This longitudinal study reiterates our understanding of
immunological profiles observed in children who are con-
stantly exposed to malaria in holoendemic regions compared
with children who are infrequently infected with malaria
TABLE 2
Association of study site, age, and sex with retention of immune responses between February 2003 and November 2004
Antibody response ELISPOT
3D7 FVO 3D7
OR 95% CI OR 95% CI OR 95%CI
Residence in Kisumu 3.34 0.85–15.80 2.21 0.58–8.30 2.49 0.67–10.22
Age (per year) 1.01 0.86–1.20 1.04 0.90–1.11 1.04 0.89–1.23
Female sex 0.74 0.18–2.82 0.97 0.53–1.80 0.31 0.07–1.21
CI = confidence interval; ELISPOT = enzyme-linked immunosorbent spot assays; OR = odds ratio. ORs were not calculated for ELISPOT for FVO because no child with a positive
interferon-gamma ELISPOT for FVO in 2003 retained it.
TABLE 3
Relationship between cellular immune response to MSP1 antigens
and genotype-specific parasitemia
Kisumu Nandi
OR 95% CI OR 95% CI
2003
3D7 and MSP142-3D7 0.31 0.12–0.84 0.3 0.06–1.53
FVO and MSP142-FVO – – – –
3D7 and MSP142-FVO 0.11 0.01–1.09 – –
FVO and MSP142-3D7 0.48 0.10–2.43 – –
2004
3D7 and MSP142-3D7 0.42 0.16–1.09 – –
FVO and MSP142-FVO – – – –
3D7 and MSP142-FVO – – – –
FVO and MSP142-3D7 0.92 0.25–3.51 – –
CI = confidence interval; MSP = merozoite surface protein; OR = odds ratio.
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during epidemics. Importantly, the dynamics and potential
protection against subsequent malaria infections provided by
humoral and cellular immune responses are based on inten-
sity of exposure to malaria infections. This study confirmed
prior findings that humoral immunity can persist for long
periods of time within individuals, whereas cellular immu-
nity, though protective against parasitemia in the short term,
wanes quickly in the absence of constant exposure.15,30–32
As expected, we observed a higher prevalence of positive
IgG responses to P. falciparum antigens in a holoendemic
area than a hypoendemic area.30,31 In addition, we found that
median antibody responses increased over time in Kisumu, as
would be expected in a holoendemic region where children
are constantly exposed to the parasite.30,32 In contrast, anti-
body responses in Nandi declined in magnitude between sur-
veys as the epidemic resolved and transmission decreased
(Figure 1). Interestingly, the prevalence of anti-FVO anti-
bodies was modest (60%) in 2003 in Kisumu and increased to
72% by the second survey, yet FVO was the least common of
the two variants found circulating in the population (Supple-
mental Table 2, Supplemental Information). This likely repre-
sents the known antibody cross-reactivity between FVO and
3D7 that share many B-cell epitopes.10 This finding suggests
that polyclonal antibodies developed to MSP1 3D7 may
cross-react with FVO and provide some degree of protection
in the absence of exposure. Antibody titers to both isoforms
remained high in Nandi children despite prolonged periods
of no malaria transmission.33
Malaria transmission intensity has been shown to influence
the development of protective immunity,34,35 yet studies exam-
ining the duration of malaria-specific antibody responses in
areas of hypoendemic transmission are limited. Antibodies
to MSP1 are reportedly short lived in children under 5 years
of age,36 although a study from Thailand has shown that
antibodies to some malaria antigens can persist for as long
as 30 years without reexposure to the parasite.37 This was
supported by recent data from another study in Nandi that
suggests that the half-lives of MSP1 antibodies in older chil-
dren and adults can be on the order of decades.38 Our work
is consistent with these findings, supporting the notion that
antimalarial antibody titers could be used as a surrogate of
past exposure history in children and a tool for monitoring
malaria control programs.39–41
Although we were underpowered to detect significant
changes in cellular immune responses in most cases, some
trends did emerge in our analysis. In contrast to humoral
responses, when assessing cell-mediated immunity, we
observed that children made robust IFN-γ responses to
TABLE 5
Spearman’s rho values for the correlation between humoral (Aby) and cellular (Cell) immune responses showing the correlations in Nandi
3D7 Aby 2003 3D7 Aby 2004 FVO Aby 2003 FVO Aby 2004 3D7 Cell 2003 3D7 Cell 2004 FVO Cell 2003 FVO Cell 2004
3D7 Aby 2003 1
3D7 Aby 2004 0.52 1
< 0.0005
FVO Aby 2003 0.95 0.53 1
< 0.0005 0.001
FVO Aby 2004 0.5 0.97 0.54 1
< 0.0005 < 0.0005 < 0.0005
3D7 Cell 2003 0.06 0.005 0.03 −0.008 1
NS NS NS NS
3D7 Cell 2004 −0.04 0.04 −0.04 0.04 −0.09 1
NS NS NS NS NS
FVO Cell 2003 −0.01 −0.15 −0.01 −0.16 0.23 −0.08 1
NS NS NS NS NS NS
FVO Cell 2004 0.14 0.37 0.17 0.35 −0.05 0.06 −0.04 1
NS 0.005 NS 0.01 NS NS NS
NS = nonsignificant. P values are Bonferroni-corrected for multiple comparisons.
TABLE 4
Spearman’s rho values for the correlation between humoral (Aby) and cellular (Cell) immune responses showing the correlations in Kisumu
3D7 Aby 2003 3D7 Aby 2004 FVO Aby 2003 FVO Aby 2004 3D7 Cell 2003 3D7 Cell 2004 FVO Cell 2003 FVO Cell 2004
3D7 Aby 2003 1
3D7 Aby 2004 0.53 1
0.0001
FVO Aby 2003 0.8 0.49 1
< 0.0005 0.0006
FVO Aby 2004 0.38 0.87 0.52 1
0.04 < 0.0005 0.0002
3D7 Cell 2003 0.15 0.09 0.15 0.09 1
NS NS NS NS
3D7 Cell 2004 0.13 0.06 0.16 0.04 0.47 1
NS NS NS NS 0.002
FVO Cell 2003 −0.008 −0.23 0.01 −0.12 0.46 0.08 1
NS NS NS NS 0.0002 NS
FVO Cell 2004 0.001 0.31 0.03 0.39 0.04 0.28 −0.03 1
NS NS NS 0.02 NS NS NS
NS = nonsignificant. P values are Bonferroni-corrected for multiple comparisons.
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MSP1 3D7 and FVO, but they were short lived or fell below
the threshold of detection in peripheral blood samplings over
time in the absence of exposure to malaria.15 Furthermore,
cell-mediated responses appeared more genotype specific
than antibody responses (Tables 4 and 5). IFN-γ response
was not protective against subsequent infection, similar to
another recent report.42 Although we were underpowered
to detect statistically significant relationships between para-
sitemia and antigen-specific IFN-γ responses, our results
consistently suggested that IFN-γ MSP1-recall response
was associated with lower risk of concurrent parasitemia
(Tables 4 and 5). This short-term immunity has been dem-
onstrated in other studies, including a recent treatment-
reinfection study performed in the same holoendemic site of
Kisumu that revealed that positive IFN-γ ELISPOT to 3D7-
MSP142 at baseline conferred a 73% reduction in 3-month
risk of reinfection with P. falciparum.14
Both magnitude and persistence of cellular immune
responses were affected by malaria transmission intensity.15
In February 2003, at the end of an epidemic of P. falciparum
in Nandi, both prevalence and magnitude of IFN-γ ELISPOT
response to the 3D7 antigen were higher in Nandi than in
Kisumu despite the fact that malaria transmission intensity
and prevalence of parasitemia were much greater in Kisumu.
There are several possible explanations for this phenomenon.
Children in Nandi, who might not have been previously
exposed to malaria, may have produced more vigorous
responses characteristic of a primary immune response. Chil-
dren in Kisumu, on the other hand, had smaller responses
which may have been generated by a more moderate second-
ary immune response within the context of lifelong exposure
to holoendemic malaria transmission. This finding would
support the hypothesis that constant antigenic stimulation
through repeated malaria infections can downregulate T-cell
immunity to malaria, perhaps via Treg cells, allowing asymp-
tomatic parasitemia to persist.43,44 Given the higher preva-
lence of parasitemia despite a high prevalence of positive
IFN-γ ELISPOT responses, it suggests that cellular immunity
generated to MSP142 under natural exposure conditions does
not provoke immunologic memory. This would be consistent
with the “Goldilocks principle” that posits a moderate, “just
right” antigen dose induces a more robust and long-lasting
T-cell response, whereas constant, high-level antigen stimula-
tion leads to apoptosis of activated cells.45 It also has been
suggested that intense, repeated malaria antigen exposure
could lead to tolerance or even T-cell exhaustion resulting in an
insufficient immune response during subsequent infections.46
Limitations within this cross-sectional study include our
inability to address whether differences in IgG responses
between the districts, or relative changes in antibody levels
within an individual, were the result of malaria infections
not detected and cleared before blood sampling. However,
this caveat does not diminish our findings using region as
an ecological variable for malaria exposure. We also did
not measure functional immunity; however, other studies
using functional antibody assays suggest duration of immune
response engendered is an important variable to consider
when assessing quality of protection against malaria.47 Finally,
due to the limited power of our study, we were unable to
examine more complex relationships between parasitemia
and other covariates such as nutritional status and schistoso-
miasis coinfections.
In summary, this study supports past observations about
the duration of immunity to malaria being dependent on the
quality of exposure. However, it provides additional evidence
for immunity developed by children in that a recent, primary
infection may lead to higher MSP142 IFN-γ responses than in
a child with repeated, secondary infections in a holoendemic
region.15 In a previous study of adults, the half-life of IFN-γ
secreting Th1 effector memory responses was reported to be
about 3 years,15 whereas our study of children demonstrates
a much shorter duration. Our study confirms previous
work that antibodies to MSP142 can be long lived regard-
less of age.41 We found that IFN-γ responses to MSP142
correlate to absence of concurrent parasitemia, whereas anti-
body responses do not, suggesting that control of concurrent
infection may be mediated via IFN-γ rather than antibodies.
Lastly, our data provide evidence that IFN-γ responses to
MSP142 are, by nature of T-cell epitope presentation, more
genotype specific, whereas antibody responses that are poly-
clonal may be cross-reactive to alternate variants. This study
supports the combined use of long-lived antibody titers for
monitoring malaria control programs in conjunction with
short-lived T-cell responses that would indicate recent infec-
tions; furthermore, these findings increase our understanding
of naturally acquired immunity to MSP142, a potential vac-
cine antigen. Understanding the underlying dynamics of
immunity under changing natural exposure conditions has
implications for interpreting longevity of malaria vaccine effi-
cacy and surrogate measures of protection testing in malaria-
endemic settings.
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